Northern Trust
ESLA icon

Northern Trust’s Estrella Immunopharma ESLA Stock Holding History

Northern Trust’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.3K Buy
34,861
+15,237
+78% +$19.9K ﹤0.01% 4314
2026
Q1 		$20.8K Hold
19,624
– – ﹤0.01% 4335
2025
Q4 		$30.6K Buy
+19,624
New +$37.1K ﹤0.01% 4351

Other funds holding ESLA

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Northern Trust's ESLA Position: Q2 2026 in Review

Northern Trust increased its Estrella Immunopharma (ESLA) stake by 78% in Q2 2026, buying an estimated $19.9K and bringing the position to 34,861 shares worth $36.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4314.

Northern Trust first reported a position in ESLA in Q4 2025 and has held it in 3 quarters since. 15 funds tracked by Wall St. Rank hold ESLA as of Q2 2026.

  • Northern Trust held 34,861 shares of Estrella Immunopharma worth $36.3K as of Q2 2026.
  • Northern Trust bought 15,237 Estrella Immunopharma shares in Q2 2026, an estimated $19.9K.
  • Estrella Immunopharma made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #4314 holding.
  • Northern Trust first reported a position in Estrella Immunopharma in Q4 2025 and has held it in 3 quarters since.
  • 15 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.